CTI Index Validation for Mild Cognitive Impairment Risk in T2DM Patients

A multi-stage validation study of the C-reactive protein–triglyceride–glucose index (CTI) for predicting mild cognitive impairment. The dataset includes results from a primary cohort of 1,580 patients with type 2 diabetes and an external validation cohort of 4,575 individuals from the China Health and Retirement Longitudinal Study (CHARLS). The research was authored by Yiwen Chen and last updated on 2026-05-19.

Use Cases

• Validating the CTI biomarker for predicting mild cognitive impairment based on metabolic and inflammatory status.
• Comparing model performance metrics like AUC, NRI, and IDI against other indices such as TyG.
• Investigating dose-response relationships for cognitive risk using restricted cubic spline analysis.
• Assessing the predictive value of composite markers in early stages of impaired glucose metabolism.

Strengths

• Includes a primary cohort of 1,580 patients and an external validation cohort of 4,575 individuals.
• Model performance was evaluated using multiple statistical measures: area under the curve (AUC), net reclassification improvement (NRI), and integrated discriminant improvement (IDI).
• The study design involved multi-stage validation across clinical and nationwide prospective cohorts.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• The 3.8 MB file size suggests a relatively small dataset, potentially limiting feature richness.

Provenance

Source

Primary cohort and China Health and Retirement Longitudinal Study (CHARLS).

Collection Method

Clinical study and analysis of a nationwide longitudinal survey.

Freshness

Last updated 2026-05-19 04:20:48; freshness should be verified.

Geography

Likely China, based on the CHARLS cohort.